Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Measurable residual disease in acute lymphoblastic leukemia: techniques and therapeutic utility. Clinical advances in hematology & oncology : H&O Muffly, L. 2022; 20 (7): 419-421
View details for PubMedID 35802871